Development of anti-obesity agents: drugs that target neuropeptide and neurotransmitter systems

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.3, 2008-03, pp. : 321-325

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hypothalamic Neuropeptide Systems as Targets for Potential Anti-Obesity Drugs

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 1, 2007-01 ,pp. : 11-19

Bentham Science Publishers

Access to resources Recommend Favorite

Novel anti-obesity drugs

By Proietto J. Fam B.C. Ainslie D.A. Thorburn A.W.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1317-1326

Informa Healthcare

Access to resources Recommend Favorite

Anti-obesity drug development

By Bays Harold Dujovne Carlos

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 9, 2002-09 ,pp. : 1189-1204

Informa Healthcare

Access to resources Recommend Favorite

Neuropeptide Y1 and Y5 Receptor Antagonists as Potential Anti-Obesity Drugs: Current Status

Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 11, 2014-10 ,pp. : 896-919

Bentham Science Publishers

Access to resources Recommend Favorite

Ghrelin as a Potential Anti-Obesity Target

Current Pharmaceutical Design, Vol. 9, Iss. 17, 2003-07 ,pp. : 1383-1395

Bentham Science Publishers

Access to resources Recommend Favorite